BlossomHill Therapeutics, Inc.(BLSM)

Biotechnology · San Diego, CA

$19.94+0.25 (+1.27%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

BlossomHill Therapeutics (BLSM) EV/EBIT: History & Chart | TGMCharts

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T12:05:48.570Z.

Stored calculation inputs

Calculation as of: 2026-10-06T12:05:48.570Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 579,878,330
Total debt · period ending 2026-06-30: 23,371,000
Cash · period ending 2026-06-30: 95,376,000
TTM operating income · period ending 2026-06-30: N/A

FMP input reference: ade6551c806a0b8a23cc3b9f653dfce73cf5104c20f92b5c51aa4b81f5201f45

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BLSM EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

BLSM Competitors' EV/EBIT Ratio

BLSM

BlossomHill Therapeutics, Inc.

Current

Market Cap

$579.88M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AQST

Aquestive Therapeutics, Inc.

vs BLSM

Market Cap

$573.38M

EV/EBIT Ratio

N/A

TTM Avg

78.65x

3Y Avg

78.65x

5Y Avg

78.65x

CRMD

CorMedix Inc.

vs BLSM

Market Cap

$569.56M

EV/EBIT Ratio

2.11x

TTM Avg

6.25x

3Y Avg

15.98x

5Y Avg

15.98x

ACRS

Aclaris Therapeutics, Inc.

vs BLSM

Market Cap

$596.36M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTMX

CytomX Therapeutics, Inc.

vs BLSM

Market Cap

$561.67M

EV/EBIT Ratio

N/A

TTM Avg

14.25x

3Y Avg

18.01x

5Y Avg

18.01x

DCTH

Delcath Systems, Inc.

vs BLSM

Market Cap

$547.86M

EV/EBIT Ratio

N/A

TTM Avg

189.50x

3Y Avg

189.50x

5Y Avg

189.50x

CLYM

Climb Bio, Inc.

vs BLSM

Market Cap

$632.76M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FLGT

Fulgent Genetics, Inc.

vs BLSM

Market Cap

$637.59M

EV/EBIT Ratio

N/A

TTM Avg

2.85x

3Y Avg

52.42x

5Y Avg

52.42x

ALT

Altimmune, Inc.

vs BLSM

Market Cap

$519.25M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CBIO

Crescent Biopharma, Inc.

vs BLSM

Market Cap

$517.79M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
BlossomHill Therapeutics, Inc. (BLSM)	$579.88M	N/A	N/A	N/A	N/A
Aquestive Therapeutics, Inc. (AQST)vs ›	$573.38M	N/A	78.65x	78.65x	78.65x
CorMedix Inc. (CRMD)vs ›	$569.56M	2.11x	6.25x	15.98x	15.98x
Aclaris Therapeutics, Inc. (ACRS)vs ›	$596.36M	N/A	N/A	N/A	N/A
CytomX Therapeutics, Inc. (CTMX)vs ›	$561.67M	N/A	14.25x	18.01x	18.01x
Delcath Systems, Inc. (DCTH)vs ›	$547.86M	N/A	189.50x	189.50x	189.50x
Climb Bio, Inc. (CLYM)vs ›	$632.76M	N/A	N/A	N/A	N/A
Fulgent Genetics, Inc. (FLGT)vs ›	$637.59M	N/A	2.85x	52.42x	52.42x
Altimmune, Inc. (ALT)vs ›	$519.25M	N/A	N/A	N/A	N/A
Crescent Biopharma, Inc. (CBIO)vs ›	$517.79M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

BLSM EV/EBIT Ratio Metrics

BLSM Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics